Drugs / NestaCell®
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04315987 | Jun 2020 → Feb 2021 | pneumonia | Azidus Brasil | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06097780 | Jun 2024 → Sep 2025 | Huntington disease | Azidus Brasil | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NestaCell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06097780 ↗ |
| Modality | Cell therapy | “NestaCell® is a mesenchymal stem cell therapy produced by Cellavita and proved to be safe in previous clinical trials.” NCT04315987 ↗ |
| Route | Intravenous | “A dose of 2x10\^7 cells (20 million cells) will be administered IV on days 1, 3, 5 and 7 in all subjects.” NCT04315987 ↗ |